Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $12.6 million.

  • Altimmune's Total Current Liabilities rose 45.94% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 45.94%. This contributed to the annual value of $10.5 million for FY2024, which is 13.79% down from last year.
  • Latest data reveals that Altimmune reported Total Current Liabilities of $12.6 million as of Q3 2025, which was up 36.72% from $9.2 million recorded in Q2 2025.
  • Altimmune's Total Current Liabilities' 5-year high stood at $19.1 million during Q3 2021, with a 5-year trough of $8.6 million in Q3 2024.
  • In the last 3 years, Altimmune's Total Current Liabilities had a median value of $11.4 million in 2023 and averaged $11.6 million.
  • As far as peak fluctuations go, Altimmune's Total Current Liabilities surged by 203.91% in 2021, and later slumped by 39.16% in 2025.
  • Over the past 5 years, Altimmune's Total Current Liabilities (Quarterly) stood at $18.3 million in 2021, then declined by 6.69% to $17.1 million in 2022, then decreased by 28.80% to $12.1 million in 2023, then decreased by 13.79% to $10.5 million in 2024, then spiked by 45.94% to $12.6 million in 2025.
  • Its Total Current Liabilities stands at $12.6 million for Q3 2025, versus $9.2 million for Q2 2025 and $9.8 million for Q1 2025.